Evidence map›Paper›PMID 41977268›Full record

ArticleInternational journal of molecular sciences2026

Systemic AAV9 Gene Therapy Mitigates Neuromuscular Junction Degeneration and Muscle Atrophy in a Mouse Model of CLN1 Disease.

Ewa A Ziółkowska, Albina Jablonka-Shariff, Letitia L Williams, Elizabeth M Eultgen, Matthew D Wood, Daniel A Hunter, Mark S Sands, Alison K Snyder-Warwick, Jonathan D Cooper

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ewa A ZiółkowskaDepartment of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0003-1822-3133
Albina Jablonka-ShariffDepartment of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0009-0000-8384-0117
Letitia L WilliamsDepartment of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0009-0007-5880-2574
Elizabeth M EultgenDepartment of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110, USA.
Matthew D WoodDepartment of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0001-8132-6827
Daniel A HunterDepartment of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0003-4038-0338
Mark S SandsDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0002-5559-0832
Alison K Snyder-WarwickDepartment of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0002-9882-4213
Jonathan D CooperDepartment of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0003-1339-4750

Funding

Characterizing and testing the efficacy of AAV-mediated gene therapy in a sheep model of CLN1 disease.R01NS124655 · NINDS · WASHINGTON UNIVERSITY · PI COOPER, JONATHAN D · 2022 to 2025
$1.9M
Next Generation Treatment for Krabbe DiseaseR01NS100779 · NINDS · WASHINGTON UNIVERSITY · PI SANDS, MARK S · 2018 to 2022
$1.7M
Defining and treating enteric nervous system damage in Cln1 diseaseR21NS116574 · NINDS · WASHINGTON UNIVERSITY · PI COOPER, JONATHAN D · 2020 to 2020
$454k
Defining and treating peripheral nervous system dysfunction in Cln1 diseaseR21NS126907 · NINDS · WASHINGTON UNIVERSITY · PI COOPER, JONATHAN D · 2022 to 2023
$433k
NIH HHS 1R01NS100779-00NIH HHS 1R01NS124655-00NIH HHS 1R21NS116574-00NIH HHS 1R21NS126907-00NINDS NIH HHS R01 NS100779NINDS NIH HHS R01 NS124655NINDS NIH HHS R21 NS116574NINDS NIH HHS R21 NS126907
6 · The paper itself

Abstract

CLN1 disease, caused by mutations in the PPT1 gene, is a fatal neurodegenerative lysosomal storage disorder. While central nervous system (CNS) pathology is well documented, the impact on peripheral tissues remains unclear. Having previously described severe spinal cord pathology, we investigated whether PPT1 deficiency also impacts the neuromuscular junction (NMJ) and skeletal muscle, and whether early systemic gene therapy can prevent these disease manifestations. NMJ morphology, terminal Schwann cell (tSC) coverage, and skeletal muscle structure were examined in symptomatic and end-stage

Indexed as

DependovirusGenetic TherapyMuscular AtrophyNeuromuscular JunctionNeuronal Ceroid-LipofuscinosesAnimalsDisease Models, AnimalGene Therapy AgentsGenetic VectorsMiceMice, KnockoutMuscle, SkeletalSchwann CellsAAV9 gene therapyCLN1 diseasemuscle atrophyneuromuscular junctionperipheral nervous systemterminal Schwann cells

Identifiers

PMID41977268
PMCPMC13073675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.